GlassScriptPhysician profile
Michael Pericles Siropaides
NPI 1790715035
$12,804.49
in general payments reported to CMS, 2019-2025
47 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,102 · 2020: $343 · 2021: $1,742 · 2022: $2,658 · 2023: $2,286 · 2024: $2,245 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,827 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,827.49 |
| Education | $132.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,365.00 | 2019-2025 | Jardiance |
| Abbott Laboratories | $1,292.60 | 2019-2025 | Aveir, Cardiomems, Mitraclip |
| Boston Scientific Corporation | $1,249.64 | 2019-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| Novartis Pharmaceuticals Corporation | $1,203.11 | 2019-2025 | |
| Novo Nordisk INC | $959.55 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $839.92 | 2019-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $749.44 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $591.69 | 2019-2024 | Farxiga, Brilinta |
| Impulse Dynamics (USA) INC. | $418.75 | 2022-2024 | Optimizer, Optimizer |
| E.R. Squibb & Sons, L.L.C. | $366.73 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $319.07 | 2019-2023 | Repatha |
| Biotronik INC. | $317.26 | 2019-2024 | Biomonitor |
| Medtronic, INC. | $293.09 | 2021-2024 | Harmony |
| Actelion Pharmaceuticals US, INC. | $284.75 | 2023-2024 | Opsumit, Uptravi |
| Pfizer INC. | $192.95 | 2019-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Siropaides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.